References
- Andrade LN, Vitali L, Gaspar GG, Bellissimo-Rodrigues F, Martinez R, Darini ALC. Expansion and evolution of a virulent, extensively drug-resistant (polymyxin B-resistant), QnrS1-, CTX-M-2-, and KPC-2-producing Klebsiella pneumoniae ST11 international high-risk clone. J Clin Microbiol. 2014;52(7):2530–5.
- Boev C, Kiss E. Hospital-acquired infections: current trends and prevention. Crit Care Nurs Clin North Am. 2017;29(1):51–65.
- Naparstek L, Carmeli Y, Navon-Venezia S, Banin E. Biofilm formation and susceptibility to gentamicin and colistin of extremely drug-resistant KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2014;69:1027–34.
- Dosler S, Karaaslan E, Alev Gerceker A. Antibacterial and anti-biofilm activities of melittin and colistin, alone and in combination with antibiotics against Gram-negative bacteria. J Chemother. 2016;28(2): 95–103.
- Mah TF, O’Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001;9(1):34–9.
- Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. BioMed Res Int. 2016: 2016:2475067.
- Bhattacharya M, Wozniak DJ, Stoodley P, Hall-Stoodley L. Prevention and treatment of Staphylococcus aureus biofilms. Expert Rev Anti Infect Ther. 2015;13(12):1499–516.
- Pitout JD, Laupland KB. Extended-spectrum beta-lactamase producing enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–66.
- Van-Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75(2):115–20.
- Silva A, Sousa AM, Alves D, Lourenço A, Pereira MO. Heteroresistance to colistin in Klebsiella pneumoniae is triggered by small colony variants sub-populations within biofilms. Pathog Dis. 2016;74(5). pii: ftw036.
- Mendes CAC, Burdmann EA. Polimixinas – revisão com ênfase na sua nefrotoxicidade. Rev Assoc Med Bra. 2009;55(6):752–9.
- The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0. EUCAST; 2018. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.1_Breakpoint_Tables.pdf
- Sader HS, Rhomberg PR, Flamm RK, Jones RN. Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. Diagn Microbiol Infect Dis. 2012;74(4):412–4.
- Vasoo S. Susceptibility testing for the polymyxins: two steps back, three steps forward? J Clin Microbiol. 2017;55(9): 2573–82.
- O'Toole GA. Microtiter dish biofilm formation assay. J Vis Exp. 2011;47: pii: 2437.
- Thangamani S, Mohammad H, Abushahaba MF, Hamed MI, Sobreira TJ, Hedrick VE, et al. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci Rep. 2015; 5:16407.
- Malinowski AM, McClarty BM, Robinson C, Spear W, Sanchez M, Sparkes TC, et al. Polysorbate 80 and polymyxin B inhibit Stenotrophomonas maltophilia biofilm. Diagn Microbiol Infect Dis. 2017;87(2):154–6.
- Humphries RM. Susceptibility testing of the polymyxins: where are we now? Phamacotherapy. 2015;35(1):22–7.
- Sloup RE, Cieza RJ, Needle DB, Abramovitch RB, Torres AG, Waters CM. Polysorbates prevent biofilm formation and pathogenesis of Escherichia coli O104:H4. Biofouling. 2016;32(9):1131–40.